NO974119L - Fremgangsmåte for isolering av galantamin - Google Patents
Fremgangsmåte for isolering av galantaminInfo
- Publication number
- NO974119L NO974119L NO974119A NO974119A NO974119L NO 974119 L NO974119 L NO 974119L NO 974119 A NO974119 A NO 974119A NO 974119 A NO974119 A NO 974119A NO 974119 L NO974119 L NO 974119L
- Authority
- NO
- Norway
- Prior art keywords
- galantamine
- isolating
- extraction
- instance
- extract
- Prior art date
Links
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 title abstract 4
- 229960003980 galantamine Drugs 0.000 title abstract 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 abstract 1
- LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 abstract 1
- 229930013930 alkaloid Natural products 0.000 abstract 1
- 150000003797 alkaloid derivatives Chemical class 0.000 abstract 1
- 239000000356 contaminant Substances 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 abstract 1
- IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 238000000638 solvent extraction Methods 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Extraction Or Liquid Replacement (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19509663A DE19509663A1 (de) | 1995-03-17 | 1995-03-17 | Verfahren zur Isolierung von Galanthamin |
PCT/EP1996/001094 WO1996029332A1 (de) | 1995-03-17 | 1996-03-14 | Verfahren zur isolierung von galanthamin |
Publications (3)
Publication Number | Publication Date |
---|---|
NO974119L true NO974119L (no) | 1997-09-08 |
NO974119D0 NO974119D0 (no) | 1997-09-08 |
NO316380B1 NO316380B1 (no) | 2004-01-19 |
Family
ID=7756925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19974119A NO316380B1 (no) | 1995-03-17 | 1997-09-08 | Fremgangsmåte for ekstrahering av galantamin, det derved oppnådde galantamin, galeniske preparatformer, anvendelse av galantamin samtfarmas degree ytisk preparatinneholdende galantamin |
Country Status (23)
Country | Link |
---|---|
US (5) | US5877172A (no) |
EP (2) | EP1095656B1 (no) |
JP (1) | JP3863180B2 (no) |
KR (1) | KR100427093B1 (no) |
CN (1) | CN1088460C (no) |
AT (2) | ATE247473T1 (no) |
AU (1) | AU707203B2 (no) |
CA (1) | CA2215351C (no) |
CZ (1) | CZ294722B6 (no) |
DE (3) | DE19509663A1 (no) |
DK (2) | DK0815112T3 (no) |
ES (2) | ES2206356T3 (no) |
HU (1) | HU225267B1 (no) |
IL (1) | IL117371A (no) |
MY (1) | MY114698A (no) |
NO (1) | NO316380B1 (no) |
NZ (1) | NZ304008A (no) |
PL (1) | PL184238B1 (no) |
PT (2) | PT815112E (no) |
SI (1) | SI1095656T1 (no) |
SK (1) | SK283861B6 (no) |
WO (1) | WO1996029332A1 (no) |
ZA (1) | ZA962140B (no) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19509663A1 (de) * | 1995-03-17 | 1996-09-19 | Lohmann Therapie Syst Lts | Verfahren zur Isolierung von Galanthamin |
AT402691B (de) * | 1996-01-26 | 1997-07-25 | Sanochemia Ltd | Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome |
US8603546B2 (en) * | 1999-01-11 | 2013-12-10 | Herbaceuticals Inc. | Herbal supplement for increased muscle strength and endurance for athletes |
EP1150695B1 (en) * | 1999-01-11 | 2007-02-28 | Atanas Russinov Djananov | Herbal supplement for increased muscle strength and endurance for athletes |
DE19906974C2 (de) * | 1999-02-19 | 2003-10-09 | Lohmann Therapie Syst Lts | Verwendung von Desoxypeganin zur Behandlung des Alkoholismus |
DE19906975B4 (de) * | 1999-02-19 | 2004-04-15 | Lts Lohmann Therapie-Systeme Ag | Arzneiform zur Behandlung von Alzheimer'scher Demenz |
GB9909469D0 (en) * | 1999-04-23 | 1999-06-23 | Wilkinson John A | Insectidal composition |
US6426097B2 (en) * | 2000-01-28 | 2002-07-30 | Herbaceuticals Inc. | Herbal supplement for cognitive related impairment due to estrogen loss |
CA2310926C (en) * | 2000-04-03 | 2002-10-15 | Janssen Pharmaceutica N.V. | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease |
DE10119862A1 (de) * | 2001-04-24 | 2002-11-07 | Hf Arzneimittelforsch Gmbh | Verwendung von Galanthamin zur Behandlung von Krankheitserscheinungen des zentralen Nervensystems aufgrund von Intoxikationen mit psychotropen Substanzen |
DE10129265A1 (de) * | 2001-06-18 | 2003-01-02 | Hf Arzneimittelforsch Gmbh | Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie |
DE10134038A1 (de) * | 2001-07-12 | 2003-02-06 | Hf Arzneimittelforsch Gmbh | Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit |
AU2002366555A1 (en) * | 2001-12-10 | 2003-06-23 | Washington University | Diagnostic for early stage alzheimer's disease |
US20040067934A1 (en) * | 2002-10-03 | 2004-04-08 | Parys Wim Louis Julien | Use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease |
CA2516618A1 (en) * | 2003-02-27 | 2004-09-10 | Shirankai Kyoto University Faculty Of Medicine Alumni Association Inc. | Pharmaceutical composition for treatment of drug dependence |
US20050143350A1 (en) * | 2003-11-19 | 2005-06-30 | Seed John C. | Combination drug therapy to treat obesity |
CA2551946A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Immediate, controlled and sustained release formulations of galantamine |
WO2005065662A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Solid dosage formulations of galantamine |
WO2006013546A2 (en) * | 2004-07-28 | 2006-02-09 | Ranbaxy Laboratories Limited | Process for the preparation of pure galantamine |
FR2879599B1 (fr) * | 2004-12-16 | 2007-03-23 | Centre Nat Rech Scient Cnrse | Utilisation de la chromatographie de partage centrifuge pour la purification de la galanthamine |
ITMI20042413A1 (it) * | 2004-12-17 | 2005-03-17 | Indena Spa | Processo per la preparazione di galantamina bromidrato |
WO2006099635A1 (en) * | 2005-03-17 | 2006-09-21 | Ivax Pharmaceuticals S.R.O. | Isolation of galanthamine from biological material |
US8632800B2 (en) * | 2005-05-13 | 2014-01-21 | Alza Corporation | Multilayer drug delivery system with barrier against reservoir material flow |
CN1307180C (zh) * | 2005-05-24 | 2007-03-28 | 天津大学 | 从石蒜或雪花莲属原料中提取加兰他敏的方法 |
US20070104771A1 (en) * | 2005-09-23 | 2007-05-10 | Jay Audett | Transdermal galantamine delivery system |
US7446352B2 (en) * | 2006-03-09 | 2008-11-04 | Tela Innovations, Inc. | Dynamic array architecture |
JP2009084281A (ja) | 2007-09-18 | 2009-04-23 | Ethicon Endo Surgery Inc | 術後イレウスの低減のための方法 |
CN102149398B (zh) * | 2008-09-11 | 2013-12-04 | I·B·R·以色列生物科技研究有限公司 | 雪片莲属鳞茎提取物及其用途 |
US8247405B2 (en) * | 2008-12-10 | 2012-08-21 | Conopco, Inc. | Skin lightening compositions with acetylcholinesterase inhibitors |
CN101602767B (zh) * | 2009-05-26 | 2012-01-11 | 苏州派腾生物医药科技有限公司 | 一种加兰他敏的制备方法 |
DE102009040381A1 (de) | 2009-09-07 | 2011-03-17 | Kallimopoulos, Thomas, Dr. | Verfahren zur Isolierung von Alkaloiden aus Pflanzen |
CN101787028B (zh) * | 2010-01-12 | 2012-01-04 | 恩施清江生物工程有限公司 | 一种从忽地笑中提取加兰他敏的方法 |
CN102050826B (zh) * | 2010-12-21 | 2012-11-14 | 浙江工业大学 | 一种分离加兰他敏的方法 |
BG67337B1 (bg) | 2018-05-23 | 2021-06-15 | Софарма Ад | Метод за получаване на пречистен галантамин хидробромид |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1193061B (de) * | 1961-12-20 | 1965-05-20 | Vni Chimiko Pharmazewtitschesk | Verfahren zur Gewinnung von Galanthamin-hydrobromid aus Pflanzen der Familie der Amaryllidaceen |
US4663318A (en) * | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
US5519017A (en) * | 1990-03-29 | 1996-05-21 | Lts Lohmann Therapie-Systeme Gmbh + Co. Kg | Pharmaceutic formulation for the treatment of alcoholism |
DE4010079A1 (de) * | 1990-03-29 | 1991-10-02 | Lohmann Therapie Syst Lts | Pharmazeutische formulierung zur behandlung des alkoholismus |
WO1992020327A1 (en) * | 1991-05-14 | 1992-11-26 | Ernir Snorrason | Treatment of fatigue syndrome with cholinesterase inhibitors |
US5336675A (en) * | 1991-05-14 | 1994-08-09 | Ernir Snorrason | Method of treating mania in humans |
DE4301782C1 (de) * | 1993-01-23 | 1994-08-25 | Lohmann Therapie Syst Lts | Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit |
DE4301783C1 (de) | 1993-01-23 | 1994-02-03 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil |
US5428159A (en) * | 1994-04-08 | 1995-06-27 | Ciba-Geigy Corporation | Method of manufacture of (-)-galanthamine in high yield and purity substantially free of epigalanthamine |
DE19509663A1 (de) | 1995-03-17 | 1996-09-19 | Lohmann Therapie Syst Lts | Verfahren zur Isolierung von Galanthamin |
-
1995
- 1995-03-17 DE DE19509663A patent/DE19509663A1/de active Pending
-
1996
- 1996-03-05 IL IL11737196A patent/IL117371A/xx not_active IP Right Cessation
- 1996-03-14 PT PT96907470T patent/PT815112E/pt unknown
- 1996-03-14 NZ NZ304008A patent/NZ304008A/en not_active IP Right Cessation
- 1996-03-14 AU AU51088/96A patent/AU707203B2/en not_active Expired
- 1996-03-14 PL PL96322463A patent/PL184238B1/pl unknown
- 1996-03-14 DK DK96907470T patent/DK0815112T3/da active
- 1996-03-14 SI SI9630641T patent/SI1095656T1/xx unknown
- 1996-03-14 ES ES01100944T patent/ES2206356T3/es not_active Expired - Lifetime
- 1996-03-14 EP EP01100944A patent/EP1095656B1/de not_active Expired - Lifetime
- 1996-03-14 AT AT01100944T patent/ATE247473T1/de active
- 1996-03-14 WO PCT/EP1996/001094 patent/WO1996029332A1/de active IP Right Grant
- 1996-03-14 PT PT01100944T patent/PT1095656E/pt unknown
- 1996-03-14 AT AT96907470T patent/ATE203993T1/de active
- 1996-03-14 DK DK01100944T patent/DK1095656T3/da active
- 1996-03-14 SK SK1235-97A patent/SK283861B6/sk not_active IP Right Cessation
- 1996-03-14 CZ CZ19972835A patent/CZ294722B6/cs not_active IP Right Cessation
- 1996-03-14 HU HU9802234A patent/HU225267B1/hu unknown
- 1996-03-14 JP JP52805596A patent/JP3863180B2/ja not_active Expired - Lifetime
- 1996-03-14 DE DE59610680T patent/DE59610680D1/de not_active Expired - Lifetime
- 1996-03-14 US US08/913,461 patent/US5877172A/en not_active Expired - Lifetime
- 1996-03-14 KR KR1019970706476A patent/KR100427093B1/ko not_active IP Right Cessation
- 1996-03-14 CN CN96192578A patent/CN1088460C/zh not_active Expired - Lifetime
- 1996-03-14 DE DE59607450T patent/DE59607450D1/de not_active Expired - Lifetime
- 1996-03-14 EP EP96907470A patent/EP0815112B1/de not_active Expired - Lifetime
- 1996-03-14 CA CA002215351A patent/CA2215351C/en not_active Expired - Lifetime
- 1996-03-14 ES ES96907470T patent/ES2162035T3/es not_active Expired - Lifetime
- 1996-03-15 ZA ZA962140A patent/ZA962140B/xx unknown
- 1996-03-15 MY MYPI96000954A patent/MY114698A/en unknown
-
1997
- 1997-09-08 NO NO19974119A patent/NO316380B1/no not_active IP Right Cessation
-
1998
- 1998-08-07 US US09/130,883 patent/US6194404B1/en not_active Expired - Lifetime
-
2000
- 2000-12-21 US US09/741,436 patent/US6335328B2/en not_active Expired - Lifetime
-
2001
- 2001-11-09 US US09/986,792 patent/US6573376B2/en not_active Expired - Lifetime
-
2002
- 2002-09-12 US US10/241,585 patent/US6617452B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO974119L (no) | Fremgangsmåte for isolering av galantamin | |
ATE219893T1 (de) | Tabak behandlung | |
PT616821E (pt) | Extraccao de fragrancias | |
AU7190796A (en) | Process and plant for extraction or recovery of acids from solutions of these acids | |
FI946086A (fi) | Menetelmä ja vastavirtauuttoprosessi metallien valmistamiseksi mineraaleista | |
ATE373722T1 (de) | Verfahren zur isolierung von polyhydroxyalkanoaten aus pflanzen | |
AU5997590A (en) | Supercritical fluid and near critical gas extraction of organic solvents from formed articles | |
HK1013771A1 (en) | Ginkgo biloba flavonoid extract which is terpene-free and/or has a high flavonoid heteroside content. | |
GB2214573A (en) | Method for startup of production in an oil well | |
ZA949180B (en) | Hepatoblasts and method of isolating same | |
ES2076436T3 (es) | Procedimiento de recuperacion de teicoplanina. | |
ATE199153T1 (de) | Verfahren zur herstellung von galanthamin und deren derivaten | |
ATE80418T1 (de) | Verfahren zur herstellung eines jasminextraktes und der so gewonnene extrakt. | |
AU627949B2 (en) | Method of extraction of diketones from plant material using organic acid | |
HUT73638A (en) | Process for extracting organic components of natural water and producing pharmaceutical compositions comprising this extract | |
CS689890A3 (en) | Massage ointment containing plant extracts and process for preparingthereof | |
PL280407A1 (en) | Method of obtaining purified plant lecithin | |
UA32828A (uk) | Спосіб ідентифікації присутності келіну у лікарський рослинній сировині | |
PL289404A1 (en) | Method of isolating alkaloids as individual compounds or in groups from materials of plant origin | |
PL309306A1 (en) | Method of preparing a plant material needed to set up plantations of ginkgo biloba l. | |
PL266798A1 (en) | Method of removing volatile organic solvents from postextraction waste water | |
NO920771D0 (no) | Produksjonsmetode ved bruk av sentrifugering | |
UA27960C2 (uk) | Спосіб вилучення германію із надсмольної води коксохімічного виробництва | |
AU7705687A (en) | Method for startup of production in an oil well |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1K | Patent expired |